 |
Daewoong Pharmaceutical. (Photo= Daewoong Pharmaceutical) |
[Alpha Biz= Reporter Kim Jisun] Daewoong announced on the 16th that its subsidiary, Daewoong Bio, received a suspension of tablet production operations at its Anseong plant and a suspension of manufacturing the prescription drug Clovons due to violations of pharmaceutical regulations.
This action follows a quality non-compliance ruling by the Ministry of Food and Drug Safety (MFDS) after excessive flexible materials were detected during an evaluation of Clovons tablets manufactured at the Anseong plant in March last year.
As a result of this ruling, the Anseong plant will halt all tablet production activities from August 29th to September 4th. Additionally, the manufacturing of Clovons tablets will be suspended from August 29th until March 28th next year. Last year, the revenue from tablet production at the Anseong plant, including Clovons tablets, amounted to approximately 210 billion KRW on a standalone basis.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
